No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in ...

Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...

Appointed Utpal Singh as Chief Scientific Officer in April 2025 to lead the next wave of differentiated and innovative medicines, building on Zealand Pharma’s strong peptide heritage and its ...

Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...

April 24, 2025 Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the ...

Zealand Pharma’s financial position has been significantly strengthened by the Roche partnership. As of March 2025, the company reported a cash position of DKK 8,544 million. Including the DKK ...

Appointed Utpal Singh as Chief Scientific Officer in April 2025 to lead the next wave of differentiated and innovative medicines, building on Zealand Pharma's strong peptide heritage and its ambition ...

Thank you to everyone for joining us today to discuss Zealand Pharma's results for the First Three Months of 2025. You can find the related company announcements on our website at zealandpharma.com.

European shares European shares were higher on Monday as investors reacted to U.S. President Donald Trump delaying the roll ...

Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership ...

Zealand Pharma (ZEAL) reported its financial results for Q1 2025, highlighting a revenue of 8 million DKK, primarily driven by its Segalog license agreement with Novo Nordisk. The company ...

Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of ...